EA200501456A1 - Торий- 227 для применения в радиотерапии заболевания мягких тканей - Google Patents

Торий- 227 для применения в радиотерапии заболевания мягких тканей

Info

Publication number
EA200501456A1
EA200501456A1 EA200501456A EA200501456A EA200501456A1 EA 200501456 A1 EA200501456 A1 EA 200501456A1 EA 200501456 A EA200501456 A EA 200501456A EA 200501456 A EA200501456 A EA 200501456A EA 200501456 A1 EA200501456 A1 EA 200501456A1
Authority
EA
Eurasian Patent Office
Prior art keywords
soft tissue
torium
radiotherapy
application
tissue diseases
Prior art date
Application number
EA200501456A
Other languages
English (en)
Other versions
EA008195B1 (ru
Inventor
Рой Ларсен
Эйвинд Бруланд
Original Assignee
Алгета Ас
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0308731.9A external-priority patent/GB0308731D0/en
Application filed by Алгета Ас filed Critical Алгета Ас
Publication of EA200501456A1 publication Critical patent/EA200501456A1/ru
Publication of EA008195B1 publication Critical patent/EA008195B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Radiology & Medical Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Radiation-Therapy Devices (AREA)
  • Medicinal Preparation (AREA)

Abstract

В изобретении предложен способ лечения заболевания мягких тканей у млекопитающего субъекта (предпочтительно у человека или собаки), включающий введение указанному субъекту терапевтически эффективного количества обеспечивающего направленную доставку к мягким тканям комплекса тория-227 и комплексообразующего агента, причем указанное количество является таковым, что допустимое немиелотоксическое количество радия-223 образуется in vivo в результате распада введенного тория-227.
EA200501456A 2003-04-15 2004-04-15 Применение тория-227 в лучевой терапии заболеваний мягких тканей EA008195B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0308731.9A GB0308731D0 (en) 2003-04-15 2003-04-15 Method of radiotherapy
PCT/GB2004/001654 WO2004091668A1 (en) 2003-04-15 2004-04-15 Thorium-227 for use in radiotherapy of soft tissue disease

Publications (2)

Publication Number Publication Date
EA200501456A1 true EA200501456A1 (ru) 2006-06-30
EA008195B1 EA008195B1 (ru) 2007-04-27

Family

ID=35385222

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200501456A EA008195B1 (ru) 2003-04-15 2004-04-15 Применение тория-227 в лучевой терапии заболеваний мягких тканей

Country Status (19)

Country Link
EP (1) EP1617876B1 (ru)
JP (2) JP5006032B2 (ru)
KR (2) KR101274867B1 (ru)
CN (1) CN100586484C (ru)
AU (1) AU2004229218B2 (ru)
BR (1) BRPI0409387B8 (ru)
CA (1) CA2522148C (ru)
CY (1) CY1115407T1 (ru)
DK (1) DK1617876T3 (ru)
EA (1) EA008195B1 (ru)
ES (1) ES2486845T3 (ru)
HK (1) HK1094150A1 (ru)
IL (1) IL171148A (ru)
MX (1) MXPA05010804A (ru)
NO (1) NO332931B1 (ru)
NZ (3) NZ595758A (ru)
PL (1) PL1617876T3 (ru)
PT (1) PT1617876E (ru)
ZA (1) ZA200507983B (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2486845T3 (es) * 2003-04-15 2014-08-19 Algeta Asa Torio-227 para ser usado en radioterapia de enfermedad de partes blandas
GB201002508D0 (en) * 2010-02-12 2010-03-31 Algeta As Product
GB201007354D0 (en) * 2010-04-30 2010-06-16 Algeta Asa Method
GB201105298D0 (en) * 2011-03-29 2011-05-11 Algeta Asa Pharmaceutical preparation
GB201600154D0 (en) * 2016-01-05 2016-02-17 Bayer As Isotope preparation method
GB201600153D0 (en) * 2016-01-05 2016-02-17 Bayer As Isotope preparation method
US11291680B2 (en) 2016-12-15 2022-04-05 Société des Produits Nestlé S.A. Compositions and methods that modulate white blood cells or neutrophils in a companion animal
FR3088769B1 (fr) * 2018-11-15 2020-12-25 Orano Med Procede de preparation d'au moins un generateur a haute teneur en radium-228
RU2767567C1 (ru) * 2020-10-27 2022-03-17 Станислав Анатольевич Дороватовский Комплексные соединения, содержащие в своем составе радионуклид 227Th, а также бисфосфонатный фрагмент, способы их получения, а также потенциальное применение в качестве действующего вещества в составе остеотропного радиофармацевтического лекарственного препарата

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH089553B2 (ja) * 1989-06-19 1996-01-31 アクゾ・エヌ・ヴエー α粒子放出を使用する放射免疫療法
CA2117775A1 (en) * 1992-04-13 1993-10-28 Roberta C. Cheng Process for preparing macrocyclic chelating agents and formation of chelates and conjugates thereof
MY133346A (en) * 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
NO314537B1 (no) * 1999-12-06 2003-04-07 Anticancer Therapeutic Inv Sa Reseptorbindende konjugater
NO312708B1 (no) * 2000-02-21 2002-06-24 Anticancer Therapeutic Inv Sa Radioaktive liposomer til terapi
AU4906901A (en) * 2000-02-25 2001-09-17 Dangshe Ma Actinium-225 complexes and conjugates for radioimmunotherapy
NO313180B1 (no) * 2000-07-04 2002-08-26 Anticancer Therapeutic Inv Sa Bensökende alfapartikkel emitterende radiofarmasöytika
ITMI20022411A1 (it) 2002-11-14 2004-05-15 Bracco Imaging Spa Agenti per la diagnosi e la terapia di tumori che espongono sulla superficie delle cellule proteine alterate.
ES2486845T3 (es) * 2003-04-15 2014-08-19 Algeta Asa Torio-227 para ser usado en radioterapia de enfermedad de partes blandas

Also Published As

Publication number Publication date
KR101274867B1 (ko) 2013-06-13
HK1094150A1 (en) 2007-03-23
NZ543044A (en) 2010-04-30
NZ595758A (en) 2013-02-22
EP1617876A1 (en) 2006-01-25
KR20060015507A (ko) 2006-02-17
JP2006523664A (ja) 2006-10-19
EP1617876B1 (en) 2014-05-14
NO20055390D0 (no) 2005-11-15
BRPI0409387B1 (pt) 2021-05-11
JP5468597B2 (ja) 2014-04-09
BRPI0409387B8 (pt) 2021-05-25
KR20110022743A (ko) 2011-03-07
MXPA05010804A (es) 2006-03-09
AU2004229218A1 (en) 2004-10-28
BRPI0409387A (pt) 2006-04-18
AU2004229218B2 (en) 2009-05-07
CN100586484C (zh) 2010-02-03
CA2522148C (en) 2010-07-13
IL171148A (en) 2013-12-31
JP5006032B2 (ja) 2012-08-22
CN1805760A (zh) 2006-07-19
ES2486845T3 (es) 2014-08-19
PT1617876E (pt) 2014-08-04
EA008195B1 (ru) 2007-04-27
PL1617876T3 (pl) 2015-03-31
CY1115407T1 (el) 2017-01-04
DK1617876T3 (da) 2014-07-21
NO332931B1 (no) 2013-02-04
ZA200507983B (en) 2007-03-28
NZ606996A (en) 2014-08-29
NO20055390L (no) 2006-01-16
CA2522148A1 (en) 2004-10-28
JP2012051942A (ja) 2012-03-15

Similar Documents

Publication Publication Date Title
IL172705A0 (en) Use of [3.2.0] heterocyclic compounds and analogs thereof for the treatment of cancer, inflammation and infectious diseases
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
WO2005051429A3 (en) Targeted conjugates with a modified saccharide linker
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
EA200501023A1 (ru) Терапевтические составы для лечения болезней, связанных с наличием бета-амилоида
WO2003096990A3 (en) Protein cages for the delivery of medical imaging and therapy
HK1070575A1 (en) Use of botulinum toxin for treating cardiovasculardiseases
NO20055390L (no) Thorium-227 for anvendelse i radioterapi pa mykvevssykdommer
EA200800397A1 (ru) Композиции тизанидина и способы лечения с применением композиций
ATE412646T1 (de) Zur behandlung von schmerzen geeignete therapeutische mittel
IS6558A (is) Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni
HUP0401903A2 (hu) Az ET-743 továbbfejlesztett alkalmazása daganatok kezelésére
EP1348466A3 (en) Method for treating pain with adenosine-tetraphosphates
WO2022271810A3 (en) Bicyclic peptidyl pan-ras inhibitors
PT1677806E (pt) Métodos para tratamento de entorse e distensão muscular aguda e por excesso de esforço utilizando ácido hialurónico
ATE392219T1 (de) Methoden und medizinische zusammensetzungen zur intravesikalen behandlung von blasenkrebs
BR0313081A (pt) Combinação de um inibidor de aromatase com um bisfosfanato
ATE536178T1 (de) Therapeutische anwendung von methionin zur behandlung oder prävention von mucositis
ATE297751T1 (de) Kombinationstherapie mit keratinozyten- wachstumfaktor und ein epidermis-wachstumfaktor inhibitor
CA2899234A1 (en) Method of treating fibrosis in skeletal muscle tissue
DE602004024221D1 (de) Behandlung von entzündlichen darmerkrankungen mit 2-methylen-19-nor-vitamin d verbindungen
TW200724158A (en) Combination therapy in the treatment of cancer
IL146132A0 (en) Preparations for the application of anti-infective and/or anti-inflammatory agents to external or internal parts of the human or animal body in functional and cosmetic tissue remodelling and repair treatments
DE60120917D1 (de) Kombinationspräparat zur krebstherapie
BR0311180A (pt) Métodos para o tratamento de doenças e condições respiratórias utilizando um inibidor seletivo da inos

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AZ KZ KG TJ TM